Sakar Healthcare has entered into an Agreement with the Greek client Pharmaceutical Oriented Services for process of development of patent non-infringing film coated tablets in four strengths of one of the top selling 10 molecules in anti-cancer segment. The product is prescription medicine primarily used in chronic lymphocytic leukemia (CLL) and Waldenstroms macroglobulinaemia (WM).
The worldwide market size of the product was valued at $9.7 billion in 2021 and is expected to reach $58.70 billion by 2030, with a CAGR of 23.1%. (Ref: Next Move Strategy Consulting). With an evaluated patent status, Sakar has initiated the development of the product on the approved suggested process at its research-driven API-integrated oncology formulation manufacturing unit at Bavla, near Ahmedabad, Gujarat, India; completion to which will enable client to qualify as an innovator towards new process patent.
Sakar Healthcare is an Indian pharmaceutical company engaged in the manufacturing and marketing of its own pharmaceutical formulations for domestic and international markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1849.10 |
Dr. Reddys Lab | 1352.75 |
Cipla | 1510.25 |
Lupin | 2367.85 |
Zydus Lifesciences | 975.55 |
View more.. |